Lion Street Advisors LLC Sells 489 Shares of Axsome Therapeutics, Inc. $AXSM

Lion Street Advisors LLC trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 5.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,058 shares of the company’s stock after selling 489 shares during the period. Lion Street Advisors LLC’s holdings in Axsome Therapeutics were worth $946,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of AXSM. Nuveen LLC bought a new stake in shares of Axsome Therapeutics during the 1st quarter valued at $48,185,000. 1832 Asset Management L.P. bought a new stake in shares of Axsome Therapeutics during the 1st quarter valued at $42,360,000. BVF Inc. IL raised its position in shares of Axsome Therapeutics by 21.8% during the 1st quarter. BVF Inc. IL now owns 1,690,221 shares of the company’s stock valued at $197,130,000 after purchasing an additional 302,157 shares during the period. T. Rowe Price Investment Management Inc. bought a new stake in shares of Axsome Therapeutics during the 1st quarter valued at $31,140,000. Finally, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. raised its position in shares of Axsome Therapeutics by 746.7% during the 1st quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 285,494 shares of the company’s stock valued at $33,297,000 after purchasing an additional 251,775 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $121.71 on Monday. The company has a market cap of $6.07 billion, a price-to-earnings ratio of -24.01 and a beta of 0.52. The firm’s fifty day moving average is $116.84 and its 200 day moving average is $109.84. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics, Inc. has a 52-week low of $75.56 and a 52-week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.08. The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman purchased 1,575 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were bought at an average price of $127.28 per share, with a total value of $200,466.00. Following the completion of the purchase, the director directly owned 48,212 shares in the company, valued at $6,136,423.36. This trade represents a 3.38% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Mark L. Jacobson sold 10,000 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $115.96, for a total transaction of $1,159,600.00. The disclosure for this sale can be found here. Insiders sold 243,332 shares of company stock worth $28,824,746 in the last ninety days. Company insiders own 22.30% of the company’s stock.

Wall Street Analyst Weigh In

AXSM has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on shares of Axsome Therapeutics in a research report on Thursday, July 3rd. They set an “overweight” rating and a $190.00 price objective on the stock. Bank of America boosted their target price on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Needham & Company LLC reissued a “buy” rating and issued a $150.00 target price on shares of Axsome Therapeutics in a report on Monday, August 4th. Royal Bank Of Canada boosted their target price on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an “outperform” rating in a report on Tuesday, August 5th. Finally, B. Riley initiated coverage on shares of Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $177.93.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.